Deflazacort induced stronger immunosuppression than expected

Clinical Rheumatology

Volumn 26, Issue 6, 2007, Pages 935-940

  Gonzalez Castanẽda, Rocio E ^a   Castellanos Alvarado, Estela Adriana ^a   Flores Marquez, Maria Rosa ^b   Gonzalez Perez, Oscar ^c   Luquin, Sonia ^c   Garcia Estrada, Joaquin ^a   Ramos Remus, Cesar ^b,d  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA DE OCCIDENTE   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c UNIVERSITY OF GUADALAJARA   (Mexico)

^d NONE   (Mexico)

Author keywords

Deflazacort; Immunosuppression; Prednisone

Indexed keywords

DEFLAZACORT; PREDNISONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; AUTOPSY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG METABOLISM; DRUG POTENCY; FATTY LIVER; HIPPOCAMPUS; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; KIDNEY ABSCESS; LUNG ABSCESS; MALE; MICROGLIA; MORTALITY; NERVE CELL DEGENERATION; NERVE DEGENERATION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; RATING SCALE; SKIN ABSCESS;

ANIMALS; ASTROCYTES; BACTERIAL INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOCORTICOIDS; IMMUNOSUPPRESSIVE AGENTS; MALE; MICROGLIA; NEURONS; PREDNISONE; PREFRONTAL CORTEX; PREGNENEDIONES; RATS; RATS, WISTAR;

EID: 34250740520     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-006-0223-4     Document Type: Article

References (25)

1. Starkman MN, Gebarski SS, Berent S, Schteingart DE (1992) Hippocampal formation volume, memory dysfunction, and cortisone levels in patients with Cushing's syndrome. Biol Psychiatry 32:756-765
2. Starkman MN, Giordani B, Gebarski SS, Berent S, Schork MA, Schteingart DE (1999) Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing's disease. Biol Psychiatry 46:1595-1602
3. Raber J (1998) Detrimental effects of chronic hypothalamic-pituitary-adrenal axis activation. Mol Neurobiol 18:1-22
4. Miller TP, Taylor J, Rogerson S, Mauricio M, Kennedy Q, Schatzberg A, Tinklenberg J, Yesavage J (1998) Cognitive and noncognitive symptoms in dementia patients: Relationship to cortisol and dehydroepiandrosterone. Int Psychogeriatr 10:85-96
5. Schmidt LA, Fox NA, Gooldberg MC, Smith CC, Schulkin J (1999) Effects of acute prednisone administration on memory, attention and emotion in healthy human adults. Psychoneuroendocrinology 24:461-483
6. Wolkowitz OM (1994) Prospective controlled studies of the behavioral and biological effects of exogenous corticosteroids. Psychoneuroendocrinology 19:233-255
7. Bentson J, Reza M, Winter J, Wilson G (1978) Steroids and apparent cerebral atrophy on computed tomography scans. J Comput Assist Tomogr 2:16-23
8. Snyder TJ, Ramos-Remus C, Rusell AS, Lien D, Castor W (1994) Neurobehavioral sequelae of long-term corticosteroid use in the treatment of auto-immune diseases other than SLE. Arch Clin Neuropsychol 49:188
9. Keenan PA, Jacobson MW, Soleymani RM, Mayes MD, Stress ME, Yaldoo DT (1996) The effect on memory of chronic prednisone treatment in patients with systemic disease. Neurology 47:1396-1402
10. Gonzalez-Perez O, Ramos-Remus C, Garcia-Estrada J, Luquin S (2001) Prednisone induces anxiety and glial cerebral changes in rats. J Rheumatol 28:2529-2534
11. Ramos-Remus C, González-Castañeda RE, González-Pérez O, Luquin S, García-Estrada J (2002) Chronic exposure to prednisone produces cognitive dysfunction and neurologic damage in rats. J Investig Med 50:458-464
12. Markham A, Bryson HM (1995) Deflazacort: A review of its pharmacological properties and therapeutic efficacy. Drugs 50:317-333
13. Coirini H, Flores D, Vega MC, Gonzalez Deniselle MC, De Nicola AF (1994) Binding of the anti-inflammatory steroid deflazacort to glucocorticoid receptors in brain and peripheral tissues. In vivo and in vitro studies. J Steroid Biochem Mol Biol 49:43-49
14. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates.4th ed. Academic, San Diego
15. Garcia JH, Liu KF, Ye ZR, Gutierrez JA (1997) Incomplete infarct and delayed neuronal death after transient middle cerebral artery occlusion in rats. Stroke 28:2303-2309
16. Weibel ER (1979) Stereological methods, vol. 1: Practical methods biological morphometry. Academic, London
17. Martinelli E, Ferrari P, Ripamonti A, Tuan G, Perazzi A, Assandri A (1979) Metabolism of deflazacort in the rat, dog and man. Drug Metab Dis 7:335-339
18. Scudeletti M, Pende D, Barabino A, Imbimbo B, Grifoni V, Indiveri F (1984) Effect of single oral doses of prednisone and deflazacort on human lymphocyte distribution and functions. Analysis with monoclonal antibodies. Adv Exp Med Biol 171:335-344
19. Schiatti P, Selva D, Barone D, Restelli A, Glässer A (1980) Antiinflammatory activity and other pharmacological properties of 11 β,21-dihydroxy-2′methyl-5β′H-pregna-1,4-dieno [17,16-d] oxazole-3,20-dione-21-acetate (Deflazacort)
20. Omote M, Sakai K, Mizusawa H (1994) Acute effects of deflazacort and its metabolite 21-desacetyl-deflazacort on allergic reactions. Drug Res 44:149-153
21. Horner HC, Packan DR, Sapolsky RM (1990) Glucocorticoids inhibit glucose transport in cultured hippocampal neurons and glia. Neuroendocrinology 52:57-64
22. Kraft SA, Philip Larson C, Shuer LM, Steinberg GK, Benson GV, Pearl RG (1990) Effect of hyperglycemia on neuronal changes in a rabbit model of focal cerebral ischemia. Stroke 21:447-450
23. Dhandapani KM, Hadman M, De Sevilla L, Wade MF, Mahesh VB, Brann DW (2003) Astrocyte protection of neurons: Role of transforming growth factor-beta signaling via A c-Jun-AP-1 protective pathway. J Biol Chem 278:43329-43339
24. Drew PD, Chavis JA (2000) Inhibition of microglial cell activation by cortisol. Brain Res Bull 52:391-396
25. Miller JM (2002) Drugs and endocrine and metabolic systems. In: Page C, Curtis M, Sutter M, Walker M, Hoffman B (eds) Integrated pharmacology. Mosby, London, UK, 281-326